Faculty
Geoff Uy.jpg

Geoffrey L. Uy, MD

Associate Professor
Department of Medicine
Oncology Division
Bone Marrow Transplantation & Leukemia

Clinical Interests

  • Stem-cell transplantation
  • Leukemia

Contact

  • 314-454-8304 (tel)
  • 314-454-7551 (fax)
  • 11th Floor Mid-Campus Center (office)
  • Division of Oncology
    Campus Box 8007
    Washington University Medical School
    660 South Euclid Avenue
    St. Louis, MO 63110

Research

My research is focused on the development of new agents and treatment approaches for patients with myelodysplastic syndromes and acute leukemias. I currently serve as Medical Director for Clinical Research within the Division of Oncology and serve as the institutional principal investigator for industry and cooperative group sponsored studies for acute leukemias.

My primary research focus is on modulating tumor microenvironment interactions to improve therapy for acute leukemia. In preclinical models, disrupting key molecules such as CXCR4 and VLA-4 which mediate tumor microenvironment interactions increase the sensitivity of tumor cells to chemotherapy and have translated these studies into clinical trials. I am leading an investigator initiated study of BL8040 in combination with chemotherapy for patients with relapsed acute lymphoblastic leukemia. I am also currently leading the Alliance for Clinical Trials in Oncology study for older adults with de novo AML which will test an E-selectin antagonist, GMI-1271, in combination with conventional daunorubicin plus cytarabine chemotherapy.

Finally, I am also interested in the use of next generation sequencing technologies to measure disease response in myelodsysplastic syndromes and acute myeloid leukemia. We have demonstrated that can identify and track malignant clones during therapy with hypomethylating agents and may be an alternative measure of antitumor activity to supplement traditional response criteria which are based primarily on bone marrow morphology. These next generation sequencing approaches are being tested in the context of larger randomized studies being conducted in AML.